Literature DB >> 9395744

Pathophysiology of portal hypertension.

T K Gupta1, L Chen, R J Groszmann.   

Abstract

Portal hypertension is a common clinical syndrome associated with chronic liver diseases and is characterized by a pathological increase in portal pressure. Increase in portal pressure is because of an increase in vascular resistance and an elevated portal blood flow. The site of increased intrahepatic resistance is variable and is dependent on the disease process. The site of obstruction may be: pre-hepatic, hepatic, and/or post-hepatic. In addition, part of the increased intrahepatic resistance is because of increased vascular tone. Another important factor contributing to increased portal pressure is elevated blood flow. Peripheral vasodilatation initiates the classical profile of decreased systemic resistance, expanded plasma volume, elevated splanchnic blood flow and elevated cardiac index. The elevated portal pressure leads to formation of portosystemic collaterals and oesophageal varices. Pharmacotherapy for portal hypertension is aimed at reducing both intrahepatic vascular tone and elevated splanchnic blood flow.

Entities:  

Mesh:

Year:  1997        PMID: 9395744     DOI: 10.1016/s0950-3528(97)90036-1

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  9 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 2.  Pathophysiology of portal hypertension and its clinical links.

Authors:  Yeon Seok Seo; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

3.  Gender Linked Metric Analysis of Portal Vein: A Sonographic Appraisal.

Authors:  Shikha Singh; Arvind Kumar Pankaj; Anita Rani; Pradeep Kumar Sharma; Puja Chauhan
Journal:  J Clin Diagn Res       Date:  2017-03-01

4.  Gastric mucosal resistance to acute injury in experimental portal hypertension.

Authors:  S Calatayud; M C Ramírez; M J Sanz; L Moreno; C Hernández; J Bosch; J M Piqué; J V Esplugues
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 5.  Nitric oxide and portal hypertension.

Authors:  Juan González-Abraldes; Juan Carlos García-Pagán; Jaime Bosch
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

6.  Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats.

Authors:  Savas Rafailidis; Charalampos Demertzidis; Konstantinos Ballas; Michail Alatsakis; Nikolaos Symeonidis; Theodoros Pavlidis; Kyriakos Psarras; Valentini Tzioufa-Asimakopoulou; Athanassios Sakadamis
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

7.  Splenorenal reflex modulates renal blood flow in the rat.

Authors:  Shereen M Hamza; Susan Kaufman
Journal:  J Physiol       Date:  2004-04-16       Impact factor: 5.182

8.  Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats.

Authors:  Savas Rafailidis; Konstantinos Ballas; Kyriakos Psarras; Theodoros Pavlidis; Eleni Emoniotou; Rodoula Papamichali; Georges Kalodimos; Georges Marakis; Athanassios Sakadamis; Georges Koukoulis
Journal:  J Gastroenterol       Date:  2008-11-18       Impact factor: 7.527

Review 9.  Therapeutic potential of microRNA: a new target to treat intrahepatic portal hypertension?

Authors:  Can-Jie Guo; Qin Pan; Hua Xiong; Yu-Qi Qiao; Zhao-Lian Bian; Wei Zhong; Li Sheng; Hai Li; Lei Shen; Jing Hua; Xiong Ma
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.